高级搜索

CD20+B和CD3+T淋巴细胞在乳腺浸润性导管癌和髓样癌中的表达及与预后的关系

张同先, 张 巍, 刘 芬, 刘 寒, 牛 昀

张同先, 张 巍, 刘 芬, 刘 寒, 牛 昀. CD20+B和CD3+T淋巴细胞在乳腺浸润性导管癌和髓样癌中的表达及与预后的关系[J]. 肿瘤防治研究, 2013, 40(05): 463-467. DOI: 10.3971/j.issn.1000-8578.2013.05.013
引用本文: 张同先, 张 巍, 刘 芬, 刘 寒, 牛 昀. CD20+B和CD3+T淋巴细胞在乳腺浸润性导管癌和髓样癌中的表达及与预后的关系[J]. 肿瘤防治研究, 2013, 40(05): 463-467. DOI: 10.3971/j.issn.1000-8578.2013.05.013
ZHANG Tongxian, ZHANG Wei, LIU Fen, LIU Han, NIU Yun. Expressions of CD20+B and CD3+T Lymphocytes in Infiltrating Ductal Carcinoma and Medullary Carcinoma and Their Relationships with Prognosis[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 463-467. DOI: 10.3971/j.issn.1000-8578.2013.05.013
Citation: ZHANG Tongxian, ZHANG Wei, LIU Fen, LIU Han, NIU Yun. Expressions of CD20+B and CD3+T Lymphocytes in Infiltrating Ductal Carcinoma and Medullary Carcinoma and Their Relationships with Prognosis[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 463-467. DOI: 10.3971/j.issn.1000-8578.2013.05.013

CD20+B和CD3+T淋巴细胞在乳腺浸润性导管癌和髓样癌中的表达及与预后的关系

基金项目: 国家自然科学基金资助项目(81172532);教育部长江学者和创新团队计划资助项目(TRT0743)
详细信息
    作者简介:

    张同先(1983-),男,硕士在读,主要从事乳腺肿瘤的研究

    通讯作者:

    牛昀,E-mail:yunniu2000@126.com

  • 中图分类号: R737.9

Expressions of CD20+B and CD3+T Lymphocytes in Infiltrating Ductal Carcinoma and Medullary Carcinoma and Their Relationships with Prognosis

  • 摘要: 目的 检测CD20+B、CD3+T淋巴细胞在乳腺浸润性导管癌和髓样癌中的表达分布,探讨淋巴细胞浸润与浸润性导管癌预后的关系。方法 利用免疫组织化学链霉素亲和素生物素法检测128例浸润性导管癌,44例髓样癌中CD20、CD3的表达,分析表达差异与预后的关系。组间采用Kruskal-Wallis Test,组内采用卡方检验进行分析。结果 (1)CD20+B、CD3+T这两种淋巴细胞在浸润性导管癌中分布均是瘤周多于瘤内,在髓样癌中淋巴细胞表达高于浸润性导管癌(P<0.05)。(2)浸润性导管癌中CD20+B、CD3+T淋巴细胞浸润越多,无病生存率越高(P<0.05)。(3)CD20+B淋巴细胞与组织学分级、肿瘤pTNM分期、淋巴结状态、复发情况呈负相关(P<0.05);CD3+T淋巴细胞与组织学分级、淋巴结状态、复发状态呈负相关(P<0.05)。结论 CD20+ B、CD3+ T淋巴细胞在浸润性导管癌和髓样癌中表达差异有显著性,在浸润性导管癌中其浸润程度与预后相关。

     

    Abstract: Objective To detect the expression and distribution of CD20+B and CD3+T lymphocytes in breast cancer, discuss the relationship between the prognosis of breast cancer and lymphocyte infiltration. Methods Using immunohistochemistry(IHC) to investigate the expression of CD20 and CD3 in 44 medullary carcinoma cases and 128 cases of infiltrating ductal carcinoma, the relationship between the expression differences and prognosis was analyzed, Kruskal-Wallis Test was used among groups, Chi-square Test was used within the group. Results (1)There was a higher numbers of CD20+B lymphocytes and CD3+T lymphocytes in medullary carcinoma than that in infiltrating ductal carcinoma (P<0.05). Both of CD20+B lymphocytes and CD3+T lymphocytes located in peritumoral were more than that in intratumoral of infiltrating ductal carcinoma.(2)The higher numbers of CD20+B lymphocytes and CD3+T lymphocytes was associated with the longer disease-free survival in infiltrating ductal carcinoma(P<0.05).(3)CD20+B lymphocytes was negatively correlated with tumor grade,pTNM,nodal stage and recurrence(P<0.05);CD3+T lymphocytes was negatively correlated with tumor grade,nodal stage and recurrence(P<0.05). Conclusion There are different expression of CD20+B and lymphocytes CD3+T lymphocytes in infiltrating ductal carcinoma,and medullary carcinoma and the lymphocytes was associated with prognosis.

     

  • [1] Kuroda H, Tamaru J, Sakamoto G, et al. Immunophenotype of lymphocytic infiltrationin medullary carcinoma of the breast[J].Virchows Arch, 2005,446(1):10-4.
    [2] Lim KH, Telisinghe PU, Abdullah MS, et al. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast[J]. Cancer Immun, 2010,10:3.
    [3] Coughlin CM, Vance BA, Grupp SA, et al. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy[J]. Blood, 2004, 103(6):2046-54.
    [4] Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer[J]. Clin Cancer Res, 2008, 14(16): 5220-7.
    [5] de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent[J]. Cancer Cell, 2005, 7(5):411-23.
    [6] Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword[J]. Cancer Cell, 2005, 7(5):403-5.
    [7] Lakhani SR, Ellis OI, Schnitt SJ, et al. WHO classification of tumors of the breast[M]. Lyon: Editors IARC Press, 2012, 34-47.
    [8] Wang ZK, Yang B, Liu H, et al. Regulatory T cells increase in breast cancer and in stage IV breast cancer[J]. Cancer Immunol Immunother, 2012, 61(6):911-6.
    [9] Kavalar R, Sarcevic B, Spagnoli GC, et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study[J]. Virchows Arch,2001,439(2):127-31.
    [10] Gilboa E. The promise of cancer vaccines[J]. Nat Rev Cancer, 2004, 4(5):401-11.
    [11] Schmidt M, Bhm D, von Trne C, et al.The humoral immune system has a key prognostic impact in node-negative breast cancer[J]. Cancer Res,2008 ,68(13):5405-13.
    [12] Menegaz RA, Michelin MA, Etchebehere RM, et al.Peri- and intratumoral T and B lymphocytic infiltration in breast cancer [J]. Eur J Gynaecol Oncol,2008,29(4):321-6.
    [13] Mahmoud SM, Lee AH, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast[J]. Breast Cancer Res Treat, 2012,32(2):545-53.
    [14] Nelson BH.CD20+ B cells: the other tumor-infiltrating lymphocytes[J].J Immunol,2010,185(9):4977-82.
    [15] Li Q, Lao X, Pan Q, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression[J]. Clin Cancer Res,2011,17(15):4987-95.
    [16] Andre F, Dieci MV, Dubsky P, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer [J].Clin Cancer Res,2013,19(1):28-33.
    [17] Yamaguchi R, Tanaka M, Yano A, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer[J]. Hum Pathol, 2012,43(10):1688-94.
    [18] West NR, Milne K, Truong PT, et al. T umor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer[J]. Breast Cancer Res,2011,13(6):R126.
计量
  • 文章访问数:  2112
  • HTML全文浏览量:  22
  • PDF下载量:  289
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-01-21
  • 修回日期:  2013-02-25
  • 刊出日期:  2013-05-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭